These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20210915)

  • 81. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Trends Pharmacol Sci; 2012 Jun; 33(6):312-22. PubMed ID: 22475684
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
    Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 85. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus.
    Langer O
    J Matern Fetal Neonatal Med; 2002 Apr; 11(4):218-25. PubMed ID: 12375674
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Use of noninsulin antidiabetic medications in hospitalized patients.
    Kopecky C
    Crit Care Nurs Clin North Am; 2013 Mar; 25(1):39-53. PubMed ID: 23410645
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
    Saha SA; Tuttle KR
    Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Use of oral hypoglycemic agents in patients with chronic kidney failure].
    Libardi F; Sirolli V; Cappelli P; Bonomini M
    G Ital Nefrol; 2009; 26(6):679-85. PubMed ID: 19918750
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 91. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Insulin therapy in renal disease.
    Iglesias P; Díez JJ
    Diabetes Obes Metab; 2008 Sep; 10(10):811-23. PubMed ID: 18248491
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.
    MacCallum L
    Can J Diabetes; 2014 Oct; 38(5):334-43. PubMed ID: 25284697
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Management of drugs affecting blood glucose in diabetic patients with renal failure.
    Charpentier G; Riveline JP; Varroud-Vial M
    Diabetes Metab; 2000 Jul; 26 Suppl 4():73-85. PubMed ID: 10922977
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
    McGill JB
    Curr Diabetes Rev; 2012 Jul; 8(4):257-67. PubMed ID: 22515702
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Glycemic control and treatment patterns in patients with heart failure.
    Tang WH
    Heart Fail Monit; 2006; 5(1):10-4. PubMed ID: 16547530
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.